REFERENCES
1. Bray F, Laversanne M, Sung H, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74:229-63.
2. Singh A. Global burden of five major types of gastrointestinal cancer. Prz Gastroenterol. 2024;19:236-54.
3. Wu S, Zhang Y, Lin Z, Wei M. Global burden of colorectal cancer in 2022 and projections to 2050: incidence and mortality estimates from GLOBOCAN. BMC Cancer. 2025;25:1770.
4. Grantham T, Ramachandran R, Parvataneni S, Budh D, Gollapalli S, Gaduputi V. Epidemiology of gastric cancer: global trends, risk factors and premalignant conditions. J Community Hosp Intern Med Perspect. 2023;13:100-6.
5. Sheikh M, Roshandel G, McCormack V, Malekzadeh R. Current status and future prospects for esophageal cancer. Cancers. 2023;15:765.
6. Danpanichkul P, Pang Y, Tothanarungroj P, et al. Gastrointestinal cancer statistics in 2022 and projection to 2050: GLOBOCAN estimates across 185 countries. Cancer. 2026;132:e70245.
7. Qi L, Sun M, Liu W, et al. Global esophageal cancer epidemiology in 2022 and predictions for 2050: a comprehensive analysis and projections based on GLOBOCAN data. Chin Med J. 2024;137:3108-16.
8. Reppe S, Noer A, Grimholt RM, et al. Methylation of bone SOST, its mRNA, and serum sclerostin levels correlate strongly with fracture risk in postmenopausal women. J Bone Miner Res. 2015;30:249-56.
9. Karayol R, Borroto MC, Haghshenas S, et al. MSL2 variants lead to a neurodevelopmental syndrome with lack of coordination, epilepsy, specific dysmorphisms, and a distinct episignature. Am J Hum Genet. 2024;111:1330-51.
10. Barbieri I, Tzelepis K, Pandolfini L, et al. Promoter-bound METTL3 maintains myeloid leukaemia by m6A-dependent translation control. Nature. 2017;552:126-31.
11. Quante M, Varga J, Wang TC, Greten FR. The gastrointestinal tumor microenvironment. Gastroenterology. 2013;145:63-78.
12. Tan T, Shi P, Abbas MN, et al. Epigenetic modification regulates tumor progression and metastasis through EMT (Review). Int J Oncol. 2022;60:70.
13. Kuismanen SA, Holmberg MT, Salovaara R, de la Chapelle A, Peltomäki P. Genetic and epigenetic modification of MLH1 accounts for a major share of microsatellite-unstable colorectal cancers. Am J Pathol. 2000;156:1773-9.
14. Hegi ME, Diserens AC, Gorlia T, et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med. 2005;352:997-1003.
15. Hahn MA, Li AX, Wu X, et al. Loss of the polycomb mark from bivalent promoters leads to activation of cancer-promoting genes in colorectal tumors. Cancer Res. 2014;74:3617-29.
16. Morin RD, Johnson NA, Severson TM, et al. Somatic mutations altering EZH2 (Tyr641) in follicular and diffuse large B-cell lymphomas of germinal-center origin. Nat Genet. 2010;42:181-5.
17. Jones S, Wang TL, Shih IeM, et al. Frequent mutations of chromatin remodeling gene ARID1A in ovarian clear cell carcinoma. Science. 2010;330:228-31.
19. Tsai MC, Manor O, Wan Y, et al. Long noncoding RNA as modular scaffold of histone modification complexes. Science. 2010;329:689-93.
20. Gupta RA, Shah N, Wang KC, et al. Long non-coding RNA HOTAIR reprograms chromatin state to promote cancer metastasis. Nature. 2010;464:1071-6.
21. Sawamura H, Taniguchi K, Ikeda Y, Tsuji A, Kitagishi Y, Matsuda S. Roles of gut dysbiosis, anti-proliferative proteins, and post-transcriptional regulation in carcinogenesis. J Transl Genet Genom. 2022;6:157-68.
22. Genome Atlas Research Network. Integrated genomic characterization of oesophageal carcinoma. Nature. 2017;541:169.
23. Talukdar FR, Soares Lima SC, Khoueiry R, et al. Genome-wide DNA methylation profiling of esophageal squamous cell carcinoma from global high-incidence regions identifies crucial genes and potential cancer markers. Cancer Res. 2021;81:2612-24.
24. Kawano H, Saeki H, Kitao H, et al. Chromosomal instability associated with global DNA hypomethylation is associated with the initiation and progression of esophageal squamous cell carcinoma. Ann Surg Oncol. 2014;21 Suppl 4:S696-702.
25. Hoshimoto S, Takeuchi H, Ono S, et al. Genome-wide hypomethylation and specific tumor-related gene hypermethylation are associated with esophageal squamous cell carcinoma outcome. J Thorac Oncol. 2015;10:509-17.
26. Iwagami S, Baba Y, Watanabe M, et al. LINE-1 hypomethylation is associated with a poor prognosis among patients with curatively resected esophageal squamous cell carcinoma. Ann Surg. 2013;257:449-55.
27. Dong Z, Liang X, Wu X, et al. Promoter hypermethylation-mediated downregulation of tumor suppressor gene SEMA3B and lncRNA SEMA3B-AS1 correlates with progression and prognosis of esophageal squamous cell carcinoma. Clin Exp Metastasis. 2019;36:225-41.
28. Teng H, Xue M, Liang J, et al. Inter- and intratumor DNA methylation heterogeneity associated with lymph node metastasis and prognosis of esophageal squamous cell carcinoma. Theranostics. 2020;10:3035-48.
29. Lee EJ, Lee BB, Han J, et al. CpG island hypermethylation of E-cadherin (CDH1) and integrin alpha4 is associated with recurrence of early stage esophageal squamous cell carcinoma. Int J Cancer. 2008;123:2073-9.
30. Ishii T, Murakami J, Notohara K, et al. Oesophageal squamous cell carcinoma may develop within a background of accumulating DNA methylation in normal and dysplastic mucosa. Gut. 2007;56:13-9.
31. Roth M, Abnet C, Hu N, et al. p16, MGMT, RARβ2, CLDN3, CRBP and MT1G gene methylation in esophageal squamous cell carcinoma and its precursor lesions. Oncol Rep. 2006; 15:1591-7.
32. Pu W, Wang C, Chen S, et al. Targeted bisulfite sequencing identified a panel of DNA methylation-based biomarkers for esophageal squamous cell carcinoma (ESCC). Clin Epigenetics. 2017;9:129.
33. Iwabu J, Yamashita S, Takeshima H, et al. FGF5 methylation is a sensitivity marker of esophageal squamous cell carcinoma to definitive chemoradiotherapy. Sci Rep. 2019;9:13347.
34. Li SM, He LR, Chen JW, et al. JMJD3 promotes esophageal squamous cell carcinoma pathogenesis through epigenetic regulation of MYC. Signal Transduct Target Ther. 2020;5:165.
35. Koumangoye RB, Andl T, Taubenslag KJ, et al. SOX4 interacts with EZH2 and HDAC3 to suppress microRNA-31 in invasive esophageal cancer cells. Mol Cancer. 2015;14:24.
36. Zhang E, Han L, Yin D, et al. H3K27 acetylation activated-long non-coding RNA CCAT1 affects cell proliferation and migration by regulating SPRY4 and HOXB13 expression in esophageal squamous cell carcinoma. Nucleic Acids Res. 2017;45:3086-101.
37. Nakazato H, Takeshima H, Kishino T, et al. Early-stage induction of SWI/SNF mutations during esophageal squamous cell carcinogenesis. PLoS One. 2016;11:e0147372.
38. Ozawa Y, Nakamura Y, Fujishima F, et al. Decreased expression of ARID1A contributes to infiltrative growth of esophageal squamous cell carcinoma. Tohoku J Exp Med. 2015;235:185-91.
39. Jiang YY, Jiang Y, Li CQ, et al. TP63, SOX2, and KLF5 establish a core regulatory circuitry that controls epigenetic and transcription patterns in esophageal squamous cell carcinoma cell lines. Gastroenterology. 2020;159:1311-1327.e19.
40. Choi S, Sathe A, Mathé E, Xing C, Pan Z. Identification of a putative enhancer RNA for EGFR in hyper-accessible regions in esophageal squamous cell carcinoma cells by analysis of chromatin accessibility landscapes. Front Oncol. 2021;11:724687.
41. Li W, Zheng J, Deng J, et al. Increased levels of the long intergenic non-protein coding RNA POU3F3 promote DNA methylation in esophageal squamous cell carcinoma cells. Gastroenterology. 2014;146:1714-26.e5.
42. Liang Y, Mao Q, Wang L, et al. CircIMMP2L promotes esophageal squamous cell carcinoma malignant progression via CtBP1 nuclear retention dependent epigenetic modification. Clin Transl Med. 2021;11:e519.
43. Chen P, Li S, Zhang K, et al. N6-methyladenosine demethylase ALKBH5 suppresses malignancy of esophageal cancer by regulating microRNA biogenesis and RAI1 expression. Oncogene. 2021;40:5600-12.
44. Liu Z, Wu K, Gu S, et al. A methyltransferase-like 14/miR-99a-5p/tribble 2 positive feedback circuit promotes cancer stem cell persistence and radioresistance via histone deacetylase 2-mediated epigenetic modulation in esophageal squamous cell carcinoma. Clin Transl Med. 2021;11:e545.
45. Alvarez H, Opalinska J, Zhou L, et al. Widespread hypomethylation occurs early and synergizes with gene amplification during esophageal carcinogenesis. PLoS Genet. 2011;7:e1001356.
46. Kaz AM, Wong CJ, Luo Y, et al. DNA methylation profiling in Barrett’s esophagus and esophageal adenocarcinoma reveals unique methylation signatures and molecular subclasses. Epigenetics. 2011;6:1403-12.
47. Jammula S, Katz-Summercorn AC, Li X, et al.; Oesophageal Cancer Clinical and Molecular Stratification (OCCAMS) consortium. Identification of subtypes of Barrett’s esophagus and esophageal adenocarcinoma based on DNA methylation profiles and integration of transcriptome and genome data. Gastroenterology. 2020;158:1682-1697.e1.
48. Cao L, Hu T, Lu H, Peng D. N-MYC downstream regulated gene 4 (NDRG4), a frequent downregulated gene through DNA hypermethylation, plays a tumor suppressive role in esophageal adenocarcinoma. Cancers. 2020;12:2573.
49. Singh H, Ha K, Hornick JL, et al. Hybrid stomach-intestinal chromatin states underlie human Barrett’s metaplasia. Gastroenterology. 2021;161:924-939.e11.
50. Ghosal A, Verma S, Le IT, Lee VT, de Guzman BJ, Aklog L. Analytical validation of a DNA methylation biomarker test for the diagnosis of Barrett’s esophagus and esophageal adenocarcinoma from samples collected using EsoCheck®, a non-endoscopic esophageal cell collection device. Diagnostics. 2024;14:1784.
51. Shaheen NJ, Falk GW, Iyer PG, et al. Diagnosis and management of Barrett’s esophagus: an updated ACG guideline. Am J Gastroenterol. 2022;117:559-87.
52. Schneider BJ, Shah MA, Klute K, et al. Phase I study of epigenetic priming with azacitidine prior to standard neoadjuvant chemotherapy for patients with resectable gastric and esophageal adenocarcinoma: evidence of tumor hypomethylation as an indicator of major histopathologic response. Clin Cancer Res. 2017;23:2673-80.
53. Zhao S, Allis CD, Wang GG. The language of chromatin modification in human cancers. Nat Rev Cancer. 2021;21:413-30.
54. Jassim A, Rahrmann EP, Simons BD, Gilbertson RJ. Cancers make their own luck: theories of cancer origins. Nat Rev Cancer. 2023;23:710-24.
55. Genome Atlas Research Network. Comprehensive molecular characterization of gastric adenocarcinoma. Nature. 2014;513:202-9.
56. Baba Y, Yasuda N, Bundo M, et al. LINE-1 hypomethylation, increased retrotransposition and tumor-specific insertion in upper gastrointestinal cancer. Cancer Sci. 2024;115:247-56.
57. Lin R, Qian Y, Zhang J, et al. Genome-wide DNA methylation profiling of gastric cardia cancer. J Gastroenterol Hepatol. 2023;38:290-300.
58. Suzuki K, Suzuki I, Leodolter A, et al. Global DNA demethylation in gastrointestinal cancer is age dependent and precedes genomic damage. Cancer Cell. 2006;9:199-207.
59. Zouridis H, Deng N, Ivanova T, et al. Methylation subtypes and large-scale epigenetic alterations in gastric cancer. Sci Transl Med. 2012;4:156ra140.
60. Maekita T, Nakazawa K, Mihara M, et al. High levels of aberrant DNA methylation in Helicobacter pylori-infected gastric mucosae and its possible association with gastric cancer risk. Clin Cancer Res. 2006;12:989-95.
61. Yamada H, Abe S, Charvat H, et al. Precision risk stratification of primary gastric cancer after eradication of H. pylori by a DNA methylation marker: a multicentre prospective study. Gut. 2025;74:1410-8.
62. Azarkhazin F, Tehrani GA. Detecting promoter methylation pattern of apoptotic genes Apaf1 and Caspase8 in gastric carcinoma patients undergoing chemotherapy. J Gastrointest Oncol. 2018;9:295-302.
63. Park TJ, Han S, Cho Y, Paik WK, Kim YB, Lim IK. Methylation of O6-methylguanine-DNA methyltransferase gene is associated significantly with K-ras mutation, lymph node invasion, tumor staging, and disease free survival in patients with gastric carcinoma. Cancer. 2001;92:2760-8.
64. Oue N, Sentani K, Yokozaki H, Kitadai Y, Ito R, Yasui W. Promoter methylation status of the DNA repair genes hMLH1 and MGMT in gastric carcinoma and metaplastic mucosa. Pathobiology. 2001;69:143-9.
65. Kang GH, Lee S, Kim JS, Jung HY. Profile of aberrant CpG island methylation along the multistep pathway of gastric carcinogenesis. Lab Invest. 2003;83:635-41.
66. Song SH, Jong H, Choi HH, et al. Methylation of specific CpG sites in the promoter region could significantly down-regulate p16INK4a expression in gastric adenocarcinoma. Int J Cancer. 2000;87:236-40.
67. Yu J, Hua R, Zhang Y, Tao R, Wang Q, Ni Q. DNA hypomethylation promotes invasion and metastasis of gastric cancer cells by regulating the binding of SP1 to the CDCA3 promoter. J Cell Biochem. 2020;121:142-51.
68. Jie B, Weilong C, Ming C, et al. Enhancer of zeste homolog 2 depletion induces cellular senescence via histone demethylation along the INK4/ARF locus. Int J Biochem Cell Biol. 2015;65:104-12.
69. Rezaei S, Hosseinpourfeizi MA, Moaddab Y, Safaralizadeh R. Contribution of DNA methylation and EZH2 in SRBC down-regulation in gastric cancer. Mol Biol Rep. 2020;47:5721-7.
70. Fujii S, Ochiai A. Enhancer of zeste homolog 2 downregulates E-cadherin by mediating histone H3 methylation in gastric cancer cells. Cancer Sci. 2008;99:738-46.
71. Guo L, Yang TF, Liang SC, Guo JX, Wang Q. Role of EZH2 protein expression in gastric carcinogenesis among Asians: a meta-analysis. Tumour Biol. 2014;35:6649-56.
72. Wang K, Gong Z, Chen Y, et al. KDM4C-mediated senescence defense is a targetable vulnerability in gastric cancer harboring TP53 mutations. Clin Epigenetics. 2023;15:163.
73. Wang K, Kan J, Yuen ST, et al. Exome sequencing identifies frequent mutation of ARID1A in molecular subtypes of gastric cancer. Nat Genet. 2011;43:1219-23.
74. Bao C, Guo L. MicroRNA-148a-3p inhibits cancer progression and is a novel screening biomarker for gastric cancer. J Clin Lab Anal. 2020;34:e23454.
75. Xu YJ, Fan Y. MiR-215/192 participates in gastric cancer progression. Clin Transl Oncol. 2015;17:34-40.
76. Zhao Q, Li Y, Tan BB, Fan LQ, Yang PG, Tian Y. HIF-1α induces multidrug resistance in gastric cancer cells by inducing MiR-27a. PLoS One. 2015;10:e0132746.
77. Song Y, Wang R, Li LW, et al. Long non-coding RNA HOTAIR mediates the switching of histone H3 lysine 27 acetylation to methylation to promote epithelial-to-mesenchymal transition in gastric cancer. Int J Oncol. 2019;54:77-86.
78. Chen J, Li Y, Zheng Q, et al. Circular RNA profile identifies circPVT1 as a proliferative factor and prognostic marker in gastric cancer. Cancer Lett. 2017;388:208-19.
79. Huang X, Li Z, Zhang Q, et al. Circular RNA AKT3 upregulates PIK3R1 to enhance cisplatin resistance in gastric cancer via miR-198 suppression. Mol Cancer. 2019;18:71.
80. Li J, Gao J, Tian W, Li Y, Zhang J. Long non-coding RNA MALAT1 drives gastric cancer progression by regulating HMGB2 modulating the miR-1297. Cancer Cell Int. 2017;17:44.
81. Yan J, Dang Y, Liu S, Zhang Y, Zhang G. LncRNA HOTAIR promotes cisplatin resistance in gastric cancer by targeting miR-126 to activate the PI3K/AKT/MRP1 genes. Tumour Biol. 2016;37:16345-16355.
82. Chan TH, Qamra A, Tan KT, et al. ADAR-mediated RNA editing predicts progression and prognosis of gastric cancer. Gastroenterology. 2016;151:637-650.e10.
83. Chen J, Li L, Liu TY, et al. CPEB3 suppresses gastric cancer progression by inhibiting ADAR1-mediated RNA editing via localizing ADAR1 mRNA to P bodies. Oncogene. 2022;41:4591-605.
84. Liu T, Yang S, Sui J, et al. Dysregulated N6-methyladenosine methylation writer METTL3 contributes to the proliferation and migration of gastric cancer. J Cell Physiol. 2020;235:548-62.
85. Yang DD, Chen ZH, Yu K, et al. METTL3 promotes the progression of gastric cancer via targeting the MYC pathway. Front Oncol. 2020;10:115.
86. Pi J, Wang W, Ji M, et al. YTHDF1 promotes gastric carcinogenesis by controlling translation of FZD7. Cancer Res. 2021;81:2651-65.
87. Ajani JA, D'Amico TA, Bentrem DJ, et al. Gastric cancer, version 2.2025, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2025;23:169-91.
89. Toyota M, Ahuja N, Ohe-Toyota M, Herman JG, Baylin SB, Issa JP. CpG island methylator phenotype in colorectal cancer. Proc Natl Acad Sci U S A. 1999;96:8681-6.
90. Ogino S, Nosho K, Kirkner GJ, et al. CpG island methylator phenotype, microsatellite instability, BRAF mutation and clinical outcome in colon cancer. Gut. 2009;58:90-6.
91. Shiovitz S, Bertagnolli MM, Renfro LA, et al.; Alliance for clinical trials in oncology. CpG island methylator phenotype is associated with response to adjuvant irinotecan-based therapy for stage III colon cancer. Gastroenterology. 2014;147:637-45.
92. Kang KJ, Min BH, Ryu KJ, et al. The role of the CpG island methylator phenotype on survival outcome in colon cancer. Gut Liver. 2015;9:202-7.
93. Dahlin AM, Palmqvist R, Henriksson ML, et al. The role of the CpG island methylator phenotype in colorectal cancer prognosis depends on microsatellite instability screening status. Clin Cancer Res. 2010;16:1845-55.
94. Derks S, Postma C, Moerkerk PT, et al. Promoter methylation precedes chromosomal alterations in colorectal cancer development. Cell Oncol. 2006;28:247-57.
95. Chan AO, Broaddus RR, Houlihan PS, Issa JP, Hamilton SR, Rashid A. CpG island methylation in aberrant crypt foci of the colorectum. Am J Pathol. 2002;160:1823-30.
96. Lee KH, Lee JS, Nam JH, et al. Promoter methylation status of hMLH1, hMSH2, and MGMT genes in colorectal cancer associated with adenoma-carcinoma sequence. Langenbecks Arch Surg. 2011;396:1017-26.
97. Li JS, Riggins K, Yang L, et al. DNA methylation profiling at base-pair resolution reveals unique epigenetic features of early-onset colorectal cancer in underrepresented populations. Clin Epigenetics. 2025;17:11.
98. Park SK, Baek HL, Yu J, et al. Is methylation analysis of SFRP2, TFPI2, NDRG4, and BMP3 promoters suitable for colorectal cancer screening in the Korean population? Intest Res. 2017;15:495-501.
99. Tsai YH, Lai YH, Chen SJ, Cheng YC, Pai TW. DNA methylation biomarker discovery for colorectal cancer diagnosis assistance through integrated analysis. Cancer Inform. 2025;24:11769351251324545.
100. Mitomi H, Fukui N, Tanaka N, et al. Aberrant p16INK4a methylation is a frequent event in colorectal cancers: prognostic value and relation to mRNA expression and immunoreactivity. J Cancer Res Clin Oncol. 2010;136:323-31.
101. Li N, Luo C, Chen Y, et al. Identification and validation of blood leukocyte DNA methylation biomarkers for early detection of colorectal neoplasm. Chin Med J. 2026;139:2334-45.
102. Mo S, Dai W, Wang H, et al. Early detection and prognosis prediction for colorectal cancer by circulating tumour DNA methylation haplotypes: a multicentre cohort study. EClinicalMedicine. 2023;55:101717.
103. Symonds EL, Pedersen SK, Murray DH, et al. Circulating tumour DNA for monitoring colorectal cancer-a prospective cohort study to assess relationship to tissue methylation, cancer characteristics and surgical resection. Clin Epigenetics. 2018;10:63.
104. Zhu D, Li J, Zhang W, et al. Highly specific multiplex DNA methylation detection for liquid biopsy of colorectal cancer. Clin Chim Acta. 2025;565:120026.
105. Bushara O, Wester JR, Jacobsen D, et al. Clinical and histopathologic characterization of SETD2-mutated colorectal cancer. Hum Pathol. 2023;131:9-16.
106. Yuan H, Li N, Fu D, et al. Histone methyltransferase SETD2 modulates alternative splicing to inhibit intestinal tumorigenesis. J Clin Invest. 2017;127:3375-91.
107. Shuai W, Wu J, Chen S, et al. SUV39H2 promotes colorectal cancer proliferation and metastasis via tri-methylation of the SLIT1 promoter. Cancer Lett. 2018;422:56-69.
108. Wu X, Li R, Song Q, et al. JMJD2C promotes colorectal cancer metastasis via regulating histone methylation of MALAT1 promoter and enhancing β-catenin signaling pathway. J Exp Clin Cancer Res. 2019;38:435.
109. Zhang C, Yu R, Li S, et al. KRAS mutation increases histone H3 lysine 9 lactylation (H3K9la) to promote colorectal cancer progression by facilitating cholesterol transporter GRAMD1A expression. Cell Death Differ. 2025;32:2225-38.
110. Jin W, Wang J, Feng Y, Chen B, Hu Z. HDAC3-mediated deacetylation of p21 stabilizes protein levels and promotes 5-FU resistance in colorectal cancer cells. Adv Cancer Biol Metastasis. 2025;14:100136.
111. Tan Y, Zhang S, Zhu H, et al. Histone deacetylase 6 selective inhibitor ACY1215 inhibits cell proliferation and enhances the chemotherapeutic effect of 5-fluorouracil in HCT116 cells. Ann Transl Med. 2019;7:2.
112. Lee DH, Won HR, Ryu HW, Han JM, Kwon SH. The HDAC6 inhibitor ACY‑1215 enhances the anticancer activity of oxaliplatin in colorectal cancer cells. Int J Oncol. 2018;53:844-54.
113. Zhang Y, Wang S, Kang W, et al. CREPT facilitates colorectal cancer growth through inducing Wnt/β-catenin pathway by enhancing p300-mediated β-catenin acetylation. Oncogene. 2018;37:3485-500.
114. Becker WR, Nevins SA, Chen DC, et al. Single-cell analyses define a continuum of cell state and composition changes in the malignant transformation of polyps to colorectal cancer. Nat Genet. 2022;54:985-95.
115. Li S, Yang M, Teng S, et al. Chromatin accessibility dynamics in colorectal cancer liver metastasis: uncovering the liver tropism at single cell resolution. Pharmacol Res. 2023;195:106896.
116. Kogo R, Shimamura T, Mimori K, et al. Long noncoding RNA HOTAIR regulates polycomb-dependent chromatin modification and is associated with poor prognosis in colorectal cancers. Cancer Res. 2011;71:6320-6.
117. Zhang J, Li Q, Xue B, He R. MALAT1 inhibits the Wnt/β-catenin signaling pathway in colon cancer cells and affects cell proliferation and apoptosis. Bosn J Basic Med Sci. 2020;20:357-64.
118. Xu J, Xiao Y, Liu B, et al. Exosomal MALAT1 sponges miR-26a/26b to promote the invasion and metastasis of colorectal cancer via FUT4 enhanced fucosylation and PI3K/Akt pathway. J Exp Clin Cancer Res. 2020;39:54.
119. Hsiao KY, Lin YC, Gupta SK, et al. Noncoding effects of circular RNA CCDC66 promote colon cancer growth and metastasis. Cancer Res. 2017;77:2339-50.
120. Sun Y, Cao Z, Shan J, et al. Hsa_circ_0020095 promotes oncogenesis and cisplatin resistance in colon cancer by sponging miR-487a-3p and modulating SOX9. Front Cell Dev Biol. 2020;8:604869.
121. Sun W, Su Y, Zhang Z. Characterizing m6A modification factors and their interactions in colorectal cancer: implications for tumor subtypes and clinical outcomes. Discov Oncol. 2024;15:457.
122. Chen H, Gao S, Liu W, et al. RNA N6-methyladenosine methyltransferase METTL3 facilitates colorectal cancer by activating the m6A-GLUT1-mTORC1 axis and is a therapeutic target. Gastroenterology. 2021;160:1284-1300.e16.
123. Li T, Hu PS, Zuo Z, et al. METTL3 facilitates tumor progression via an m6A-IGF2BP2-dependent mechanism in colorectal carcinoma. Mol Cancer. 2019;18:112.
124. Xiang S, Liang X, Yin S, Liu J, Xiang Z. N6-methyladenosine methyltransferase METTL3 promotes colorectal cancer cell proliferation through enhancing MYC expression. Am J Transl Res. 2020;12:1789-806.
125. Imperiale TF, Porter K, Zella J, et al.; BLUE-C Study Investigators. Next-generation multitarget stool DNA test for colorectal cancer screening. N Engl J Med. 2024;390:984-93.
126. Davidson KW, Barry MJ, Mangione CM, et al.; US Preventive Services Task Force. Screening for colorectal cancer: US preventive services task force recommendation statement. JAMA. 2021;325:1965-77.
127. Jin P, Kang Q, Wang X, et al. Performance of a second-generation methylated SEPT9 test in detecting colorectal neoplasm. J Gastroenterol Hepatol. 2015;30:830-3.
128. US Food and Drug Administration. PMA P130001: FDA summary of safety and effectiveness data. 2016. Available from: https://www.accessdata.fda.gov/cdrh_docs/pdf13/p130001b.pdf [Last accessed on 14 Jul 2026].
129. Aronson M, Palma L, Semotiuk K, et al. Canadian consensus for the assessment and testing of Lynch syndrome. J Med Genet. 2025;62:326-34.
130. Chung DC, Gray DM 2nd, Singh H, et al. A cell-free DNA blood-based test for colorectal cancer screening. N Engl J Med. 2024;390:973-83.
131. US Food and Drug Administration. Shield-P230009. Available from: https://www.fda.gov/medical-devices/recently-approved-devices/shield-p230009 [Last accessed on 14 Jul 2026].
132. Kuang C, Park Y, Augustin RC, et al. Pembrolizumab plus azacitidine in patients with chemotherapy refractory metastatic colorectal cancer: a single-arm phase 2 trial and correlative biomarker analysis. Clin Epigenetics. 2022;14:3.
133. Smyth EC, Lagergren J, Fitzgerald RC, et al. Oesophageal cancer. Nat Rev Dis Primers. 2017;3:17048.
134. Guinney J, Dienstmann R, Wang X, et al. The consensus molecular subtypes of colorectal cancer. Nat Med. 2015;21:1350-6.
135. Imperiale TF, Ransohoff DF, Itzkowitz SH, et al. Multitarget stool DNA testing for colorectal-cancer screening. N Engl J Med. 2014;370:1287-97.
136. Shigaki H, Baba Y, Watanabe M, et al. LINE-1 hypomethylation in gastric cancer, detected by bisulfite pyrosequencing, is associated with poor prognosis. Gastric Cancer. 2013;16:480-7.
137. Inamura K, Yamauchi M, Nishihara R, et al. Tumor LINE-1 methylation level and microsatellite instability in relation to colorectal cancer prognosis. J Natl Cancer Inst. 2014;106:dju195.
